Theranica

Executive Summary

Theranica is a US-Israeli digital health company pioneering non-invasive neuromodulation for neurological disorders, with a focus on migraine. Its flagship product, Nerivio, is a wearable, drug-free device that uses remote electrical neuromodulation (REN) controlled via smartphone to treat acute migraine. The device is FDA-cleared and clinically validated, offering an alternative for patients who cannot tolerate or have contraindications to pharmacological treatments. By leveraging personalized neurotechnology, Theranica addresses a significant unmet need in neurology, where many patients are underserved by current therapies. The company has demonstrated strong clinical evidence, with multiple studies showing efficacy and safety, and has expanded its target indications beyond migraine to include other pain conditions. With a growing market for non-opioid pain management and digital therapeutics, Theranica is well-positioned to capture share in the neurostimulation space. Its strategy includes direct-to-consumer sales and partnerships with insurers and employers to improve access. Continued innovation and regulatory expansion are key to its growth trajectory.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance for expanded indication (e.g., pediatric migraine or chronic pain)75% success
• Q4 2026Major payer coverage decision or partnership for Nerivio60% success
• TBDPositive clinical trial results for next-generation device or new therapeutic area40% success